INTERVIEW: Glivec and the Indian healthcare conundrum
This article was originally published in Scrip
Executive Summary
It is not the easiest of times to be heading Novartis India. The Supreme Court decision to decline a patent for Glivec (imatinib mesylate), which sparked a global debate on the alleged profiteering practices of big pharma, shows that the challenges are many for those in leadership positions in out-of-pocket markets like India.